-
公开(公告)号:US20130253029A1
公开(公告)日:2013-09-26
申请号:US13876757
申请日:2011-09-27
IPC分类号: C07D209/52 , A61K45/06 , A61K31/403
CPC分类号: C07D209/52 , A61K31/403 , A61K45/06
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法,优选通过调节神经和/或精神病学靶标(GPCR和/或非GPCR) 。
-
公开(公告)号:US20100298384A1
公开(公告)日:2010-11-25
申请号:US12517280
申请日:2007-12-04
申请人: Mohamed Takhi , Jagattaran Das , Javed Iqbal , Natesan Selvakumar , Sreenivas Kandepu , M. Sitaram Kumar
发明人: Mohamed Takhi , Jagattaran Das , Javed Iqbal , Natesan Selvakumar , Sreenivas Kandepu , M. Sitaram Kumar
IPC分类号: A61K31/4439 , C07D263/30 , C07D277/28 , C07D413/14 , A61K31/422 , A61K31/427 , A61P31/04
CPC分类号: C07D413/14 , C07D417/14
摘要: The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents
摘要翻译: 本发明涉及具有抗菌活性的式(I)的恶唑烷酮化合物,其药学上可接受的盐,其立体异构体,其前药,包含它们的药物组合物及其作为治疗剂的用途
-
公开(公告)号:US20140228303A1
公开(公告)日:2014-08-14
申请号:US14126268
申请日:2012-06-13
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
IPC分类号: A61K31/7048 , A61K31/70 , C07H19/01 , C07H7/04
CPC分类号: A61K31/7048 , A61K31/70 , C07D309/10 , C07D401/04 , C07D493/08 , C07H7/04 , C07H9/04 , C07H13/04 , C07H13/12 , C07H15/04 , C07H19/01
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
-
公开(公告)号:US08455479B2
公开(公告)日:2013-06-04
申请号:US12863016
申请日:2009-01-23
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04 , A61K31/551 , A61P3/10
CPC分类号: C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物以及通过抑制二肽基肽酶IV(DPP-IV)来治疗或预防可被调节或归一化的一种或多种病症的方法。
-
公开(公告)号:US20140378540A1
公开(公告)日:2014-12-25
申请号:US14344628
申请日:2012-09-12
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
IPC分类号: C07D309/10 , C07D493/08
CPC分类号: C07D309/10 , C07D493/08 , C07H7/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2(SGLT-2)调节或归一化的病症或疾病的药物组合物。
-
公开(公告)号:US20120165320A1
公开(公告)日:2012-06-28
申请号:US13380744
申请日:2010-06-22
申请人: Rajseh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajseh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/422 , C07D413/14 , A61K31/4439 , A61K31/5377 , A61P25/00 , A61K31/403 , C07D417/10 , A61K31/541 , A61K31/551 , A61K31/5513 , C07D413/10 , C07D403/10
CPC分类号: C07D221/22 , C07D209/52 , C07D401/10 , C07D409/04 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/08
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。
-
公开(公告)号:US20110245258A1
公开(公告)日:2011-10-06
申请号:US13130440
申请日:2009-11-18
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Sandeep Kanwar , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Sandeep Kanwar , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/4985 , C07D487/04 , A61K31/519 , A61P31/04 , A61P31/16 , A61P31/06
CPC分类号: C07D487/04 , C07D263/20 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.
摘要翻译: 本发明涉及式I的新型苯基恶唑烷酮化合物,其药学上可接受的类似物,互变异构形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成新型式I化合物或其药学上可接受的类似物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供了包含新颖的式I化合物和使用它们的方法的药物组合物。 本发明的化合物可用作抗微生物剂,对许多需氧和/或厌氧革兰氏阳性和/或革兰氏阴性病原体有效,如葡萄球菌,链球菌,肠球菌,细菌,梭菌,流感嗜血杆菌 ,莫拉氏菌,耐酸菌,如结核分枝杆菌,以及耐盐霉菌属的霉菌和肠球菌。
-
公开(公告)号:US08906913B2
公开(公告)日:2014-12-09
申请号:US13380744
申请日:2010-06-22
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/5355 , C07D413/10 , C07D209/52 , C07D417/14 , C07D491/08 , C07D221/22 , C07D487/04 , C07D413/14 , C07D409/04 , C07D471/04 , C07D417/10 , C07D401/10
CPC分类号: C07D221/22 , C07D209/52 , C07D401/10 , C07D409/04 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/08
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。
-
公开(公告)号:US08841306B2
公开(公告)日:2014-09-23
申请号:US13130440
申请日:2009-11-18
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Sandeep Kanwar , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Sandeep Kanwar , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/33 , C07D413/14 , C07D417/12 , C07D487/04 , C07D413/12 , C07D263/20
CPC分类号: C07D487/04 , C07D263/20 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.
摘要翻译: 本发明涉及式I的新型苯基恶唑烷酮化合物,其药学上可接受的类似物,互变异构形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成新型式I化合物或其药学上可接受的类似物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供了包含新颖的式I化合物和使用它们的方法的药物组合物。 本发明的化合物可用作抗微生物剂,对许多需氧和/或厌氧革兰氏阳性和/或革兰氏阴性病原体有效,如葡萄球菌,链球菌,肠球菌,细菌,梭菌,流感嗜血杆菌 ,莫拉氏菌,耐酸菌,如结核分枝杆菌,以及耐盐霉菌属的霉菌和肠球菌。
-
公开(公告)号:US09133116B2
公开(公告)日:2015-09-15
申请号:US13876757
申请日:2011-09-27
IPC分类号: C07D209/52 , A61K31/403 , A61K45/06
CPC分类号: C07D209/52 , A61K31/403 , A61K45/06
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法,优选通过调节神经和/或精神病学靶标(GPCR和/或非GPCR) 。
-
-
-
-
-
-
-
-
-